I have been wondering what the extent of the “product development” is. My assumption was that they would take the pro test, integrate the buffer and put some snazzy artwork on it. The more time that has passed I have been wondering whether the development is more extensive. Perhaps removing the plastic casing (a la Binax now test) or similar lower cost innovation. Pure speculation of course but an nda would allow for an exciting unveiling at product launch.
Currently watching both Angle and Avacta (similar market caps) take different trajectories towards major news - both companies due something over next couple of months but timing and outcome unclear . Angle looking for FDA approval (which isn’t nailed on) and seems to be building nicely into this milestone (so far!), Avacta currently on a different trajectory as we know. Given we are now well into the AVA6K trial and notwithstanding bad news/a lacklustre investor day I am hopeful we start to build nicely into Q4.
So this is the week when we start talking about winter readiness, Lord Bethell comes out of hiding to talk up LFTs, whispers point towards readiness by end of the month and, tomorrow, Avacta host a seminar on “pandemic preparedness”.
Will it really be the case that after 3 months of complete silence on the LFT the first we hear from the Avacta diagnostic team is at this conference?
I can’t shake the feeling that this week (tomorrow?) we will get an update.
I am guessing that the Jupiter might be that (1) Avacta management now waiting to bundle news together - as per Myles theory (2) news is still a few weeks away (3) possible flurry of non-Avacta LFT news in the near term (omega LFT choice?) to distract investors
The current pro-use Avacta device leaves a lot of scope for Medusa to add their magic. Having taken the (inferior S/S) Orient and Acon tests over the last few days it’s noticeable how much better they are than the initial Innova packs; integrated buffer, convenient perforations, clear instructions.
Add in the above plus 98/99 plus the snap-off swab plus UK made and the Avacta test starts to look very attractive to a marketeer.
Timelines suggest some kind of scale up issue to be the case - however the last RNS stated “Manufacturing scale up continues to progress well” - I can’t see this statement being permitted if there is a chronic problem here.
I am still wondering whether the hold up is due to product reconfigurations (eg pre-prepared buffer, single pack units, leafleting and general kitting) required for the HUA pack.
Controversial point here but in my view the most accurate scoop over the last 18months was actually by Sticky when he managed to get the CE-mark delay information. Given the relative ease of getting this it’s almost certain that the GAD output numbers are known to a large cohort. I sincerely hope that this and other intelligence re: EU contracts, HUA, Medusa capacity come good…
Who was it that suggested making a movie of the Avacta saga? Our main man missing in action following a trip to Avacta towers, gagged with an AffiDx between the teeth by Sir Al. To be released “shortly”. Poor soul could be there for years.
The CEO did say that he would update on uk capacity as soon as he could do so. Since then we know that Omega won’t be manufacturing the Avacta test.
I had expected an update by now to confirm the position and allow us to move on with certainty. I am torn between (a) the CEO doesn’t want to update the market on bad news, perhaps until that RoW capacity is secured (b) discussions remain ongoing in relation to GAD capacity
At this stage I feel like there is limited downside to full transparency on LFT capacity. The market seems to have (rightly or wrongly) assumed the worst.